{"title": null, "author": null, "url": "https://aspr.hhs.gov/AboutASPR/ProgramOffices/BARDA/Pages/default.aspx", "hostname": "aspr.hhs.gov", "description": null, "sitename": null, "date": "2023-09-11", "cleaned_text": "Project NextGen BARDA Supports Development of Next-Generation Medical Countermeasures BARDA, in collaboration with the National Institute of Allergy and Infectious Diseases, is supporting the development of next generation medical countermeasures, including vaccines and therapeutics, to protect Americans from public health security threats such as coronaviruses. [Learn More](https://medicalcountermeasures.gov/nextgen) The Biomedical Advanced Research and Development Authority (BARDA) provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks; pandemic influenza (PI), and emerging infectious diseases (EID). Together with its industry partners, BARDA promotes the advanced development of medical countermeasures to protect Americans and respond to 21st century health security threats. Dr. Gary Disbrow is the Director of the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and "}